Showing results (281-290 of 679) with videos related to
Sort By:
Pageof 68
Scientific Reports|August 25, 2017
Logic programming reveals alteration of key transcription factors in multiple myelomaBertrand Miannay, Stéphane Minvielle, Olivier Roux, et al.Leukemia & Lymphoma|January 4, 2012
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myelomaCyrille Touzeau, Nicolas Blin, Aline Clavert, et al.American Journal of Hematology|July 27, 2005
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004Morie A Gertz, Ray Comenzo, Rodney H Falk, et al.Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 12, 2017
Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adultsMarina Illiaquer, Berthe-Marie Imbert-Marcille, Thierry Guillaume, et al.Blood|March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Jae Hoon Lee, Philippe Moreau, et al.BMC Cancer|June 15, 2014
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathwaySylvanie Surget, Géraldine Descamps, Carole Brosseau, et al.Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.Pageof 68